Shares of MannKind Corporation climbed more than 2% in premarket trading Wednesday, on track to extend gains from the ...

Cipla secures CDSCO approval for Afrezza, its inhaled insulin, marking a breakthrough in diabetes management with innovative ...

Inhaled insulin is a new option for type 2 diabetic patients with poor glycemic control on oral monotherapy. A rapid-acting inhaled insulin (Exubera) was approved recently for treatment of type 1 ...

India has the 2nd highest burden of diabetes worldwideCDSCO decision follows existing approvals in the U.S.A. and ...

Company plans to meet with FDA regarding potential sNDA submission in 1H 2025Call planned today at 8:30 a.m. (ET) to discuss company’s diabetes ...

Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...

MannKind today announced six-month results from its Phase 3 INHALE-1 study of Afrezza insulin inhalation powder in children.

Indian regulator Central Drugs Standard Control Organisation (CDSCO) has approved Cipla to exclusively distribute and market ...

Inhaled insulin still carries a risk of hypoglycemia and, as such, does not avoid the need for blood glucose monitoring, which can be as unpopular as injecting insulin. In type 1 diabetes ...

The inhaler - by which a spray deposits insulin directly into the lungs - is being tested in the UK after successful experiments in Canada. The spray could be a lifesaver for thousands of ...

Cipla receives approval to market Afrezza, a rapid-acting insulin inhaler, offering a needle-free solution for diabetes ...